2026/01/01 by Jennifer Ross, Kimberly Boeser, Matthew Hordyk +6 · 1 voice
Economics, Econometrics and Finance · Immunology and Microbiology · Medicine · #Antibiotic Use and Resistance #Antibiotics Pharmacokinetics and Efficacy #Health Systems, Economic Evaluations, Quality of Life
paper · pdf · doi:10.1017/ash.2026.10329
openalex publication_date 2026/01/01 · openalex created_date 2026/04/02 · openalex updated_date 2026/07/27
We previously characterized a reduction in unscheduled care following implementation of ID pharmacist review of outpatient parenteral antimicrobial therapy plans for patients discharging from acute care. In this report we demonstrate the cost avoidance that this intervention would be expected to generate for patients enrolled in value-based-care plans.